RA Capital Healthcare Fund LP's Form 4 filing
Cytek Biosciences, Inc. (CTKB) · filed Feb 22, 2022
- Accession no.
- 0001104659-22-025736
- Filed
- Feb 22, 2022, 5:22 PM ET
- Trade date
- Feb 17-22, 2022
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $7.70M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| RA Capital Healthcare Fund LPCIK 0001315082 | Director |
| Ra Capital Management, L.P.CIK 0001346824 | Director |
| Kolchinsky PeterCIK 0001384859 | Director |
| Shah Rajeev M.CIK 0001619841 | Director |
| RA Capital Nexus Fund II, L.P.CIK 0001825376 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 17, 2022 | Common Stock | PPurchaseAcquired | +166,229 | $14.78 | +$2,457,263.57 | 10,271,886 | Indirect | |
| Feb 18, 2022 | Common Stock | PPurchaseAcquired | +166,229 | $14.12 | +$2,346,388.83 | 10,438,115 | Indirect | |
| Feb 22, 2022 | Common Stock | PPurchaseAcquired | +214,922 | $13.46 | +$2,892,054.91 | 10,653,037 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.